Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study 'Immunomodulation and Multiple Sclerosis Epidemiology 5' (IMSE 5)

MLA

Rosengren, V., et al. Clinical Effectiveness and Safety of Dimethyl Fumarate for Patients Treated at Least 5 Years in the Swedish Post-Market Surveillance Study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5). 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1293956372&authtype=sso&custid=ns315887.

APA

Rosengren, V., Ekström, E., Forsberg, L., Kågström, S., Berglund, A., Hillert, J., Nilsson, P., Dahle, C., Svenningsson, A., Lycke, J., Landtblom, A.-M., Burman, J., Martin, C., Sundström, P., Gunnarsson, M., Piehl, F., & Olsson, T. (2021). Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5).

Chicago

Rosengren, V., E. Ekström, L. Forsberg, S. Kågström, A. Berglund, J. Hillert, P. Nilsson, et al. 2021. “Clinical Effectiveness and Safety of Dimethyl Fumarate for Patients Treated at Least 5 Years in the Swedish Post-Market Surveillance Study ‘Immunomodulation and Multiple Sclerosis Epidemiology 5’ (IMSE 5).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1293956372&authtype=sso&custid=ns315887.